Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 84Neoplasm Metastasis 59Prostatic Neoplasms 57Leukemia, Myeloid, Acute 57Melanoma 49Multiple Myeloma 47Colorectal Neoplasms 44Lung Neoplasms 43Pancreatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 38Lymphoma 37Neoplasms 30Myelodysplastic Syndromes 30Leukemia, Lymphocytic, Chronic, B-Cell 30Squamous Cell Carcinoma of Head and Neck 28Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 24Ovarian Neoplasms 24Burkitt Lymphoma 21Rectal Neoplasms 20Lymphoma, Follicular 19Colonic Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 18Sarcoma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Lymphoma, Mantle-Cell 17Glioma 17Head and Neck Neoplasms 16

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Biopsy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡